<SEC-DOCUMENT>0000905718-19-001011.txt : 20191231
<SEC-HEADER>0000905718-19-001011.hdr.sgml : 20191231
<ACCEPTANCE-DATETIME>20191231160927
ACCESSION NUMBER:		0000905718-19-001011
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20190630
FILED AS OF DATE:		20191231
DATE AS OF CHANGE:		20191231

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Gabriel Capital Management Ltd.
		CENTRAL INDEX KEY:			0001765871
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-38807
		FILM NUMBER:		191319570

	BUSINESS ADDRESS:	
		STREET 1:		JERUSALEM TECHNOLOGY PARK
		STREET 2:		BUILDING 1B, BOX 70
		CITY:			MALHA, JERUSALEM
		STATE:			L3
		ZIP:			9651
		BUSINESS PHONE:		97226490400

	MAIL ADDRESS:	
		STREET 1:		JERUSALEM TECHNOLOGY PARK
		STREET 2:		BUILDING 1B, BOX 70
		CITY:			MALHA, JERUSALEM
		STATE:			L3
		ZIP:			9651

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Anchiano Therapeutics Ltd.
		CENTRAL INDEX KEY:			0001534248
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		1/3 HIGH-TECH VILLAGE
		STREET 2:		GIVAT RAM, P.0. BOX 39264
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9139102
		BUSINESS PHONE:		972-2-5486555

	MAIL ADDRESS:	
		STREET 1:		1/3 HIGH-TECH VILLAGE
		STREET 2:		GIVAT RAM, P.0. BOX 39264
		CITY:			JERUSALEM
		STATE:			L3
		ZIP:			9139102

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	BioCancell Ltd.
		DATE OF NAME CHANGE:	20111104
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>anchiano_fm3jan12020.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0206</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2019-06-30</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001534248</issuerCik>
        <issuerName>Anchiano Therapeutics Ltd.</issuerName>
        <issuerTradingSymbol>ANCN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001765871</rptOwnerCik>
            <rptOwnerName>Gabriel Capital Management Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>JERUSALEM TECHNOLOGY PARK</rptOwnerStreet1>
            <rptOwnerStreet2>BUILDING 1B, BOX 70</rptOwnerStreet2>
            <rptOwnerCity>MALHA, JERUSALEM</rptOwnerCity>
            <rptOwnerState>L3</rptOwnerState>
            <rptOwnerZipCode>96951</rptOwnerZipCode>
            <rptOwnerStateDescription>ISRAEL</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
            <officerTitle></officerTitle>
            <otherText></otherText>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Ordinary Shares, no par value per share</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>5034150</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <derivativeTable>
        <derivativeHolding>
            <securityTitle>
                <value>Warrants (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>1.932</value>
            </conversionOrExercisePrice>
            <exerciseDate>
                <footnoteId id="F3"/>
            </exerciseDate>
            <expirationDate>
                <value>2023-06-29</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Ordinary Shares</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>3834396</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>I</value>
                </directOrIndirectOwnership>
                <natureOfOwnership>
                    <value>See Footnote</value>
                    <footnoteId id="F2"/>
                </natureOfOwnership>
            </ownershipNature>
        </derivativeHolding>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The ordinary shares, no par value (the &quot;Ordinary Shares&quot;), of Anchiano Therapeutics Ltd. (the &quot;Issuer&quot;) are held as American Depository Shares (&quot;ADSs&quot;), with each ADS representing five Ordinary Shares.</footnote>
        <footnote id="F2">Gabriel Capital Management Ltd. (the &quot;Reporting Person&quot;) is the management company to Shavit Capital Fund III (US), L.P. (&quot;Shavit III&quot;) and certain other affiliated funds (collectively with Shavit III, the &quot;Shavit Funds&quot;). Gabriel Leibler (&quot;Mr. Leibler&quot;) is the sole shareholder of the sole shareholder of the Reporting Person. As of the filing date of this Form 3: Shavit III held 611,261 ADSs, representing 3,056,305 Ordinary Shares, and warrants exercisable for up to 2,314,286 Ordinary Shares; and the other Shavit Funds held in the aggregate 395,569 ADSs, representing 1,977,845 Ordinary Shares, and warrants exercisable for up to 1,520,110 Ordinary Shares. Pursuant to Rule 16a-1(a)(2) under the Securities Exchange Act of 1934, as amended, each of the Reporting Person's, each Shavit Fund's and Mr. Leibler's beneficial ownership is limited to its pecuniary interest, if any, in such securities.</footnote>
        <footnote id="F3">The warrants are currently exercisable.</footnote>
    </footnotes>

    <remarks>As of June 30, 2019, the Issuer no longer qualifies as a foreign private issuer. The Reporting Person is filing this Form 3 on or before January 1, 2020, in accordance with the published guidance of the Securities and Exchange Commission. See SEC Division of Corporation Finance, Compliance and Disclosure Interpretations, Exchange Act Section 16 and Related Rules and Forms, Interp. 101.02 (Aug. 11, 2010).</remarks>

    <ownerSignature>
        <signatureName>/s/ Gabriel Leibler, Sole Director and Shareholder of Gabriel Capital Management Ltd.</signatureName>
        <signatureDate>2019-12-31</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
